Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma.
Kumar S, Jagannath S, Weisel KC, Rosiñol L, Leleu X, Dimopoulos MA, Kastritis E, Siegel DS, Monge J, Du J, de la Rubia J, Asensi Cantó P, Lee JH, Mateos MV, Puertas B, Gozzetti A, Dytfeld D, Ocio EM, Blade J, Ozaki S, Beksac M, Escalante F, Nagaraj M, Hassan R, Bonar N, Spin P, Shokoohi M, Siddiqui M, Wang D, Hou K, West MED, Hampp C, Green J, Humblet O, Breskin A, Harnett J, Ge W, Sobel RE, Jalbert JJ, Kroog GS, Rodriguez Lorenc K, Ma Q, Durie BGM.
Kumar S, et al. Among authors: lee jh.
Blood Cancer J. 2026 Mar 25;16(1):44. doi: 10.1038/s41408-026-01466-2.
Blood Cancer J. 2026.
PMID: 41881954
Free PMC article.
Clinical Trial.